comparemela.com

Latest Breaking News On - Dianthus therapeutics inc - Page 4 : comparemela.com

Dianthus Therapeutics (NASDAQ:DNTH) Price Target Increased to $51 00 by Analysts at Raymond James

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) had its price objective hoisted by equities researchers at Raymond James from $34.00 to $51.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Raymond James’ price target would suggest a potential upside of 112.32% from the stock’s […]

Stifel nicolausRaymond jamesRaymond jameDianthus therapeutics incJefferies financial groupNorthern trust corpVanguard group incTower research capitalDianthus therapeuticsGet free reportFinancial groupCapital advisorsPoint capitalTrust corpDianthus therapeutics daily

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) Dianthus Therapeutics, Inc. DNTH, a clinical-stage biotechnology company dedicated to…

United statesDianthus therapeutics incAmerican academy of neurologyAmerican academyAnnual meetingReaking news

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCompensation committeeDianthus therapeutics incNasdaq listing ruleDianthus therapeuticsEquity inducement planNew york city

Dianthus Therapeutics, Inc (NASDAQ:DNTH) Sees Significant Increase in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,070,000 shares, a growth of 27.3% from the February 29th total of 840,400 shares. Approximately 5.0% of the company’s stock are short sold. […]

Stifel nicolausJefferies financial groupDimensional fund advisorsCitigroup incAcadian asset managementDianthus therapeutics incTower research capitalNorthern trust corpDianthus therapeuticsGet free reportResearch capitalFund advisorsTrust corpFinancial groupDianthus therapeutics dailyNasdaq dnth

Dianthus Therapeutics, Inc (NASDAQ:DNTH) Sees Significant Increase in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 1,070,000 shares, a growth of 27.3% from the February 29th total of 840,400 shares. Based on an average trading volume of 127,100 shares, […]

Stifel nicolausDianthus therapeutics incJefferies financial groupCitigroup incDimensional fund advisorsDianthus therapeutics company profileTower research capitalAcadian asset managementNorthern trust corpDianthus therapeuticsGet free reportFinancial groupResearch capitalFund advisorsTrust corpDianthus therapeutics daily

vimarsana © 2020. All Rights Reserved.